Photoacoustic Ultrasound Mammoscopy for evaluating screening detected abnormalit...
Photoacoustic Ultrasound Mammoscopy for evaluating screening detected abnormalities in the breast
X-ray mammography is the mainstay of breast cancer screening programs. It is estimated that between 20 - 50% of abnormal screening mammograms will prove to be negative. The paradigm in diagnosis is to establish whether a lesion is...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SOLUS
Smart optical and ultrasound diagnostics of breast cancer
4M€
Cerrado
CPP2021-008751
Nueva Generación de Dispositivos de Imagen Molecular en Mama...
104K€
Cerrado
BREAST CT
Dedicated CT of the Female Breast Feasibility optimizatio...
3M€
Cerrado
LOUISA 3D
Innovative 3 dimensional optoacoustic imaging for safe breas...
71K€
Cerrado
DPI2013-42236-R
TECNOLOGIAS AVANZADAS DE IMAGEN ULTRASONICA PARA DIAGNOSTICO...
82K€
Cerrado
Información proyecto PAMMOTH
Duración del proyecto: 56 meses
Fecha Inicio: 2016-10-25
Fecha Fin: 2021-06-30
Líder del proyecto
UNIVERSITEIT TWENTE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
X-ray mammography is the mainstay of breast cancer screening programs. It is estimated that between 20 - 50% of abnormal screening mammograms will prove to be negative. The paradigm in diagnosis is to establish whether a lesion is benign or malignant. All the imaging techniques conventionally used today – diagnostic x-ray, ultrasonography and magnetic resonance imaging have many limitations, leading to multiple and/or repeat imaging and often unnecessary biopsy. This leads to physical, psychological and economic burdens felt at individual, familial and societal levels.
With an aging population, high incidence of breast cancer and tightening health-care budgets, there is an urgent requirement for a non-invasive method for in-depth assessment of the screening-detected lesion. In PAMMOTH we will showcase such an imager, combining photoacoustic and ultrasound imaging. With the use of quantitative image reconstruction of multi-wavelength photoacoustic data, information is gained of the vascular and oxygen status of the lesion relating to tumor physiology and function. From the ultrasound part, we derive ultrasound reflection from the lesion in a manner superior to conventional breast ultrasonography, relating to anatomic features and extent of a tumor. This information will enable the radiologist to come to a diagnosis accurately and rapidly without the use of contrast agents, without pain and discomfort to the patient, while being cost-effective and not requiring complex infrastructure.
Four excellent academic groups, three dynamic SMEs, and a hospital come together with support from key stakeholders in an Advisory group, to push beyond the state-of-the-art in science and technology to achieve the PAMMOTH imager. For the SMEs, in addition to tremendous improvements in individual product lines, the new integrated diagnostic imaging instrument opens up completely new market opportunities.
We expect PAMMOTH to have a strong economic and clinical impact.